CA2409652A1 - Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux - Google Patents

Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux Download PDF

Info

Publication number
CA2409652A1
CA2409652A1 CA002409652A CA2409652A CA2409652A1 CA 2409652 A1 CA2409652 A1 CA 2409652A1 CA 002409652 A CA002409652 A CA 002409652A CA 2409652 A CA2409652 A CA 2409652A CA 2409652 A1 CA2409652 A1 CA 2409652A1
Authority
CA
Canada
Prior art keywords
her2
aromatase inhibitor
antibody against
human
exemestane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002409652A
Other languages
English (en)
Inventor
Giorgio Massimini
Gabriella Piscitelli
Dinesh Purandare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2409652A1 publication Critical patent/CA2409652A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de traitement d'un être humain soufrant d'un désordre hormono-dépendant, caractérisé par une surexpression de HER2, ce procédé consistant à administrer à cet être humain un inhibiteur d'aromatases, par exemple exémestane, fadrozole, létrozole et anastrozole, ainsi qu'un anticorps dirigé contre HER2, par exemple trastuzumab, en doses efficaces pour produire un effet thérapeutique synergique ou superadditif.
CA002409652A 2000-05-15 2001-04-19 Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux Abandoned CA2409652A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
US09/571,355 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (fr) 2000-05-15 2001-04-19 Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux

Publications (1)

Publication Number Publication Date
CA2409652A1 true CA2409652A1 (fr) 2001-11-22

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002409652A Abandoned CA2409652A1 (fr) 2000-05-15 2001-04-19 Inhibiteurs des aromatases et anticorps monoclonaux anti-her2 utiles en tant qu'agents antitumoraux

Country Status (20)

Country Link
EP (1) EP1282440A1 (fr)
JP (1) JP2003533490A (fr)
KR (1) KR20030014223A (fr)
CN (1) CN1429118A (fr)
AU (1) AU784617B2 (fr)
BR (1) BR0110732A (fr)
CA (1) CA2409652A1 (fr)
CZ (1) CZ20023748A3 (fr)
EA (1) EA005931B1 (fr)
EE (1) EE200200622A (fr)
HK (1) HK1054200A1 (fr)
HU (1) HUP0301877A2 (fr)
IL (1) IL152389A0 (fr)
MX (1) MXPA02011194A (fr)
NO (1) NO20025302L (fr)
NZ (1) NZ523004A (fr)
PL (1) PL360153A1 (fr)
SK (1) SK16022002A3 (fr)
WO (1) WO2001087334A1 (fr)
ZA (1) ZA200209815B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
KR20030007640A (ko) 2000-05-19 2003-01-23 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
CA2434611A1 (fr) * 2001-01-26 2002-09-19 Pharmacia Italia Spa Procede combine de traitement de troubles hormonodependants
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
JP4660094B2 (ja) 2002-03-26 2011-03-30 ゼンサン （シャンハイ） サイ−テク． リミテッド 新生物を治療するためのＥｒｂＢ３に基づく方法および組成物
BR0312484A (pt) * 2002-07-01 2008-01-08 Savient Pharmaceuticals Inc compostos e métodos para tratamento terapêutico
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
EP2322217A3 (fr) * 2004-07-16 2011-09-28 Pfizer Products Inc. Traitement combiné pour malignités non hematologiques par anticorps anti-IGF-1R
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
NZ590431A (en) 2005-02-23 2012-08-31 Genentech Inc Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
CA2626337C (fr) 2005-10-19 2015-12-29 Chavah Pty Ltd Reduction des effets secondaires des inhibiteurs de l'aromatase employes dans le traitement du cancer du sein
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2408817B1 (fr) 2009-03-20 2016-03-16 F.Hoffmann-La Roche Ag Anticorps anti-her di-spécifiques
WO2010136569A1 (fr) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulateurs de la signalisation her2 chez des patients exprimant her2 souffrant d'un cancer de l'estomac
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (fr) 2010-05-19 2011-11-24 Genentech, Inc. Prédiction de réponses à un inhibiteur de her
WO2012069466A1 (fr) 2010-11-24 2012-05-31 Novartis Ag Molécules multi-spécifiques
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102068429B (zh) * 2010-12-28 2011-12-14 西南大学 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法
CA2842375A1 (fr) 2011-08-17 2013-02-21 Erica Jackson Anticorps anti-neureguline et utilisations associees
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CA2857114A1 (fr) 2011-11-30 2013-06-06 Genentech, Inc. Mutations dans erbb3 dans des cancers
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
CA2865082A1 (fr) 2012-03-27 2013-10-03 Genentech, Inc. Diagnostic et traitements concernant des inhibiteurs de her3
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
CA2889298C (fr) 2012-11-30 2024-01-02 Anton Belousov Identification de patients ayant besoin d'une cotherapie par un inhibiteur de pd-l1
CA2965372C (fr) 2014-10-22 2023-09-05 Havah Therapeutics Pty Ltd Procede de reduction de densite mammaire monographique et/ou de risque de cancer du sein
CA3002562A1 (fr) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Procedes de reduction de la densite mammaire a la mammographie et/ou du risque de cancer du sein
WO2017194554A1 (fr) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polythérapies pour le traitement du cancer
CN107417791B (zh) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 抗人ErbB2双特异性抗体、其制备方法及用途
EP3976048A4 (fr) 2019-06-03 2023-07-12 Havah Therapeutics Pty Ltd Formulations pharmaceutiques et systèmes pour l'administration d'un agent androgène et d'un inhibiteur de l'aromatase, et procédés d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Also Published As

Publication number Publication date
CN1429118A (zh) 2003-07-09
JP2003533490A (ja) 2003-11-11
CZ20023748A3 (cs) 2003-04-16
MXPA02011194A (es) 2003-03-10
HK1054200A1 (zh) 2003-11-21
AU5630901A (en) 2001-11-26
SK16022002A3 (sk) 2003-04-01
NO20025302D0 (no) 2002-11-05
HUP0301877A2 (hu) 2003-09-29
ZA200209815B (en) 2003-12-03
PL360153A1 (en) 2004-09-06
KR20030014223A (ko) 2003-02-15
NO20025302L (no) 2002-11-05
NZ523004A (en) 2004-09-24
EA200201213A1 (ru) 2003-04-24
EE200200622A (et) 2004-06-15
EP1282440A1 (fr) 2003-02-12
EA005931B1 (ru) 2005-08-25
BR0110732A (pt) 2003-02-04
IL152389A0 (en) 2003-05-29
AU784617B2 (en) 2006-05-18
WO2001087334A1 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
AU784617B2 (en) Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents
US20050032759A1 (en) Antitumor combined therapy
AU2012229147B2 (en) Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
JP5220315B2 (ja) 抗ＥｐＣＡＭ免疫グロブリン
JP2023085422A (ja) 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
WO2017205216A1 (fr) Association de pembrolizumab et d'abémaciclib pour le traitement du cancer
Perry et al. Trastuzumab
WO2023172906A1 (fr) Conjugués anticorps-médicament comprenant des agonistes de sting, associations et procédés d'utilisation
WO2023230605A1 (fr) Méthode de traitement d'une tumeur solide
NZ614427B2 (en) Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued